Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.54 SEK | -2.71% | +0.12% | +6.99% |
04-17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
04-17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
Sales 2024 * | 617M 56.39M 77.1M | Sales 2025 * | 788M 72M 98.44M | Capitalization | 570M 52.08M 71.21M |
---|---|---|---|---|---|
Net income 2024 * | -107M -9.78M -13.37M | Net income 2025 * | -28M -2.56M -3.5M | EV / Sales 2024 * | 1.39 x |
Net Debt 2024 * | 289M 26.42M 36.12M | Net Debt 2025 * | 201M 18.37M 25.12M | EV / Sales 2025 * | 0.98 x |
P/E ratio 2024 * |
-5.32
x | P/E ratio 2025 * |
-19.9
x | Employees | 116 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.49% |
Latest transcript on Orexo AB
1 day | -2.71% | ||
1 week | +0.12% | ||
Current month | +6.16% | ||
1 month | +11.76% | ||
3 months | +14.54% | ||
6 months | +21.44% | ||
Current year | +6.99% |
Managers | Title | Age | Since |
---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 52 | 11-09-30 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 57 | 22-08-31 |
Edward Kim
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 19-04-10 | |
James Noble
CHM | Chairman | 65 | 20-04-15 |
Director/Board Member | 62 | 01-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 16.54 | -2.71% | 19,414 |
24-04-25 | 17 | 0.00% | 8,963 |
24-04-24 | 17 | +2.53% | 7,316 |
24-04-23 | 16.58 | +5.07% | 20,373 |
24-04-22 | 15.78 | -4.48% | 33,396 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.99% | 51.97M | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |
- Stock Market
- Equities
- ORX Stock